Clarus Nixes $86M IPO After Testosterone Drug Falls Flat
Venture capital-backed Clarus Therapeutics Inc. officially called off plans to raise $86.25 million in an initial public offering Wednesday, roughly six months after a Food and Drug Administration committee voted against...To view the full article, register now.
Already a subscriber? Click here to view full article